

Maximizing Efficiency for UHPLC LC-MS/MS Method Development in clinical drug monitoring

ASMS 2013 MP111

Sven Vedder¹, Anja Grüning¹, Klaus Bollig²,
Brigitte Richrath², Robert Ludwig¹

¹Shimadzu Europa GmbH, Duisburg, Germany,

²Shimadzu Germany GmbH, Duisburg, Germany

Maximizing Efficiency for UHPLC LC-MS/MS Method Development in clinical drug monitoring

1. Introduction

With the development of highly sensitive and fast LC-MS/MS instruments, the triple quadrupole technology has found its way into clinical drug monitoring and is the method of choice for a number of assays. The steadily increasing number of applications in the clinical sector demands fast and efficient development of new LC-MS/MS methods. The foundation for high quality data is made through optimized chromatographic separations. Fully

automated optimization of the UHPLC method using Shimadzu's method scouting software (Fig. 1) in combination with automated MS optimization for MRM parameters are the perfect platform for the generation of new triple quad MS methods. Here we report a new and fast procedure for the LC-MS/MS method optimization for clinical drug monitoring.




Fig. 1. Combination of columns and solvents during the method scouting process.

2. Methods

2-1. LC-MS/MS parameters

One of the first steps during this automated process is the precursor ion selection, followed by the m/z adjustment of the precursor. The collision energy is optimized for the most abundant fragments and finally the fragment m/z

adjustment. Six optimization steps were performed via flow injection analysis, each taking 30 seconds (Fig. 2). The result of these automated steps was the automatic generation of a final MRM method (Table 1).

2-2. UHPLC parameters

Choosing the best HPLC column and composition of eluents are often the most important but time-consuming steps during method development. This can influence sensitivity and separation from potentially interfering matrix effects. Shimadzu Method Scouting was used to determine the best HPLC parameters for the analysis of 14 different

drugs. This allowed the combination of 6 HPLC columns with up to 16 different eluents, resulting in the investigation of up to 96 different combinations, requiring only a fraction of the time required by traditional approaches.

Maximizing Efficiency for UHPLC LC-MS/MS Method Development in clinical drug monitoring




Fig. 2. Automated MRM Optimization of the drug Verapamil on the LCMS-8040

Table 1. Optimized MRM transitions of 14 drugs

Compound	Mode	MRM transitions	Collision energy (kV)
Disopyramide	ESI positive	340.3 > 239.10 / 340.3 > 195.10	-19 / -35
Lidocaine	ESI positive	235.10 > 86.20 / 235.10 > 58.05	-22 / -39
Mexiletine	ESI positive	180.20 > 105.10 / 180.20 > 121.20	-22 / -18
Quinidine	ESI positive	325.30 > 307.10 / 325.30 > 172.05	-26 / -40
Losartan	ESI positive	423.20 > 207.00 / 423.20 > 405.00	-24 / -13
Amiodarone	ESI positive	645.90 > 100.20 / 645.90 > 86.20	-34 / 41
Amitriptyline	ESI positive	278.10 > 105.10 / 278.10 > 233.10	-27 / -18
Chlorpromazine	ESI positive	319.20 > 86.20 / 319.20 > 239.10	-23 / -28
Haloperidol	ESI positive	376.05 > 165.15 / 376.05 > 123.10	-25 / -45
Imipramine	ESI positive	281.25 > 208.00 / 281.25 > 193.10	-27 / -46
Metoprolol	ESI positive	268.25 > 116.15 / 268.25 > 133.00	-20 / -28
Nortriptyline	ESI positive	264.25 > 91.20 / 264.25 > 233.15	-30 / -15
Verapamil	ESI positive	455.20 > 165.05 / 455.20 > 150.05	-34 / -46
Warfarin	ESI negative	307.25 > 160.85 / 307.25 > 249.90	21 / 24

Maximizing Efficiency for UHPLC LC-MS/MS Method Development in clinical drug monitoring

3. Results

3-1. Method development

Traditional method development in HPLC is extremely time consuming. The combination of automated HPLC and MS method development allows the development of complete LC-MS/MS methods within a single day. In this study we show an automated method scouting procedure including the search for optimum column and mobile phase and the gradient conditions. The combination with the fully automated MRM-optimization by flow injection allows a

fast development of a final method for the analysis of clinical drugs. Here we show methods automatically generated for the separation, identification and quantification of a mixture of drugs by the use of 7 different solvents and 6 different columns. The primary step to elucidate the best HPLC conditions out of various combinations is the automated batch creation via method scouting software from Shimadzu (Fig. 3).

Analysis	Vial	Tray	Inj. Vol	AutoPurge	Sample Name	Column Position	PumpA	PumpB	Data File
1	-1	1	0.5	✓	MedMix_Poster	11K C18.60C.66MPa	A:Water	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0011cd
2	91	1	0.5		MedMix_Poster	11K C18.60C.66MPa	A:Water	A:ACN	MedMix_Kin C18_Water_ACN_5_95_0021cd
3	-1	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	A:Water	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0043cd
4	91	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	A:Water	A:ACN	MedMix_SynHydro_Water_ACN_5_95_0044cd
5	-1	1	0.5		MedMix_Poster	35SynFusion.60C.66MPa	A:Water	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0061cd
6	91	1	0.5		MedMix_Poster	35SynFusion.60C.66MPa	A:Water	A:ACN	MedMix_SynFusion_Water_ACN_5_95_0066cd
7	-1	1	0.5		MedMix_Poster	4Shim C18.60C.66MPa	A:Water	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0071cd
8	91	1	0.5		MedMix_Poster	4Shim C18.60C.66MPa	A:Water	A:ACN	MedMix_Shim C18_Water_ACN_5_95_0088cd
9	-1	1	0.5		MedMix_Poster	5Shim C8.60C.66MPa	A:Water	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0091cd
10	91	1	0.5		MedMix_Poster	5Shim C8.60C.66MPa	A:Water	A:ACN	MedMix_Shim C8_Water_ACN_5_95_0101cd
11	-1	1	0.5		MedMix_Poster	6Shim Phen.60C.66MPa	A:Water	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0111cd
12	91	1	0.5		MedMix_Poster	6Shim Phen.60C.66MPa	A:Water	A:ACN	MedMix_Shim Phen_Water_ACN_5_95_0121cd
13	-1	1	0.5	✓	MedMix_Poster	11K C18.60C.66MPa	A:Water	B:MeOH	Poster2019Scout_01WEqLibDataMedMix_0131cd
14	91	1	0.5		MedMix_Poster	11K C18.60C.66MPa	A:Water	B:MeOH	MedMix_Kin C18_Water_MeOH_5_95_0141cd
15	-1	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	A:Water	B:MeOH	Poster2019Scout_01WEqLibDataMedMix_0151cd
16	91	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	A:Water	B:MeOH	MedMix_SynHydro_Water_MeOH_5_95_0161cd
17	-1	1	0.5		MedMix_Poster	35SynFusion.60C.66MPa	A:Water	B:MeOH	Poster2019Scout_01WEqLibDataMedMix_0171cd
18	91	1	0.5		MedMix_Poster	35SynFusion.60C.66MPa	A:Water	B:MeOH	MedMix_SynFusion_Water_MeOH_5_95_0181cd
19	-1	1	0.5		MedMix_Poster	4Shim C18.60C.66MPa	A:Water	B:MeOH	Poster2019Scout_01WEqLibDataMedMix_0191cd
20	91	1	0.5		MedMix_Poster	4Shim C18.60C.66MPa	A:Water	B:MeOH	MedMix_Shim C18_Water_MeOH_5_95_0201cd
21	-1	1	0.5		MedMix_Poster	5Shim C8.60C.66MPa	A:Water	B:MeOH	Poster2019Scout_01WEqLibDataMedMix_0211cd
22	91	1	0.5		MedMix_Poster	5Shim C8.60C.66MPa	A:Water	B:MeOH	MedMix_Shim C8_Water_MeOH_5_95_0221cd
23	-1	1	0.5		MedMix_Poster	6Shim Phen.60C.66MPa	A:Water	B:MeOH	Poster2019Scout_01WEqLibDataMedMix_0231cd
24	91	1	0.5		MedMix_Poster	6Shim Phen.60C.66MPa	A:Water	B:MeOH	MedMix_Shim Phen_Water_MeOH_5_95_0241cd
25	-1	1	0.5	✓	MedMix_Poster	11K C18.60C.66MPa	A:Water	C:MeOH_ACN	Poster2019Scout_01WEqLibDataMedMix_0251cd
26	91	1	0.5		MedMix_Poster	11K C18.60C.66MPa	A:Water	C:MeOH_ACN	MedMix_Kin C18_Water_MeOH_ACN_5_95_0261cd
27	-1	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	A:Water	C:MeOH_ACN	Poster2019Scout_01WEqLibDataMedMix_0271cd
28	91	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	A:Water	C:MeOH_ACN	MedMix_SynHydro_Water_MeOH_ACN_5_95_0281cd
29	-1	1	0.5		MedMix_Poster	35SynFusion.60C.66MPa	A:Water	C:MeOH_ACN	Poster2019Scout_01WEqLibDataMedMix_0291cd
30	91	1	0.5		MedMix_Poster	35SynFusion.60C.66MPa	A:Water	C:MeOH_ACN	MedMix_SynFusion_Water_MeOH_ACN_5_95_0301cd
31	-1	1	0.5		MedMix_Poster	4Shim C18.60C.66MPa	A:Water	C:MeOH_ACN	Poster2019Scout_01WEqLibDataMedMix_0311cd
32	91	1	0.5		MedMix_Poster	4Shim C18.60C.66MPa	A:Water	C:MeOH_ACN	MedMix_Shim C18_Water_MeOH_ACN_5_95_0321cd
33	-1	1	0.5		MedMix_Poster	5Shim C8.60C.66MPa	A:Water	C:MeOH_ACN	Poster2019Scout_01WEqLibDataMedMix_0331cd
34	91	1	0.5		MedMix_Poster	5Shim C8.60C.66MPa	A:Water	C:MeOH_ACN	MedMix_Shim C8_Water_MeOH_ACN_5_95_0341cd
35	-1	1	0.5		MedMix_Poster	6Shim Phen.60C.66MPa	A:Water	C:MeOH_ACN	Poster2019Scout_01WEqLibDataMedMix_0351cd
36	91	1	0.5		MedMix_Poster	6Shim Phen.60C.66MPa	A:Water	C:MeOH_ACN	MedMix_Shim Phen_Water_MeOH_ACN_5_95_0361cd
37	-1	1	0.5	✓	MedMix_Poster	11K C18.60C.66MPa	B:5mM NH4Ac	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0371cd
38	91	1	0.5		MedMix_Poster	11K C18.60C.66MPa	B:5mM NH4Ac	A:ACN	MedMix_Kin C18_5mM NH4Ac_ACN_5_95_0381cd
39	-1	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	B:5mM NH4Ac	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0391cd
40	91	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	B:5mM NH4Ac	A:ACN	MedMix_SynHydro_5mM NH4Ac_ACN_5_95_0401cd
41	-1	1	0.5		MedMix_Poster	35SynFusion.60C.66MPa	B:5mM NH4Ac	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0411cd
42	91	1	0.5		MedMix_Poster	35SynFusion.60C.66MPa	B:5mM NH4Ac	A:ACN	MedMix_SynFusion_5mM NH4Ac_ACN_5_95_0421cd
43	-1	1	0.5		MedMix_Poster	4Shim C18.60C.66MPa	B:5mM NH4Ac	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0431cd
44	91	1	0.5		MedMix_Poster	4Shim C18.60C.66MPa	B:5mM NH4Ac	A:ACN	MedMix_Shim C18_5mM NH4Ac_ACN_5_95_0441cd
45	-1	1	0.5		MedMix_Poster	5Shim C8.60C.66MPa	B:5mM NH4Ac	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0451cd
46	91	1	0.5		MedMix_Poster	5Shim C8.60C.66MPa	B:5mM NH4Ac	A:ACN	MedMix_Shim C8_5mM NH4Ac_ACN_5_95_0461cd
47	-1	1	0.5		MedMix_Poster	6Shim Phen.60C.66MPa	B:5mM NH4Ac	A:ACN	Poster2019Scout_01WEqLibDataMedMix_0471cd
48	91	1	0.5		MedMix_Poster	6Shim Phen.60C.66MPa	B:5mM NH4Ac	A:ACN	MedMix_Shim Phen_5mM NH4Ac_ACN_5_95_0481cd
49	-1	1	0.5	✓	MedMix_Poster	11K C18.60C.66MPa	B:5mM NH4Ac	B:MeOH	Poster2019Scout_01WEqLibDataMedMix_0491cd
50	91	1	0.5		MedMix_Poster	11K C18.60C.66MPa	B:5mM NH4Ac	B:MeOH	MedMix_Kin C18_5mM NH4Ac_MeOH_5_95_0501cd
51	-1	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	B:5mM NH4Ac	B:MeOH	Poster2019Scout_01WEqLibDataMedMix_0511cd
52	91	1	0.5		MedMix_Poster	25SynHydro.60C.66MPa	B:5mM NH4Ac	B:MeOH	MedMix_SynHydro_5mM NH4Ac_MeOH_5_95_0521cd

Fig. 3. Batch generated by the method scouting software

Table 2. Solvents and Columns used for method development

Solvent	Column
AA: Water	Kinetex 2.6μ C18 100 x 2.10 mm (Phenomenex)
AB: 5mM CH ₃ COO ⁻ NH ₄ ⁺ ; pH 8	Synergie 2.5μ Fusion -RP, 100 x 2.00 mm (Phenomenex)
AC: 0.1% Formic acid	Synergie 2.5μ Hydro-RP, 100 x 2.00 mm (Phenomenex)
AD: 10mM CH ₃ COO ⁻ NH ₄ ⁺ ; pH 4.5	Shim-pack XR-ODS II 2.2μ, 100 x 2.00 mm (Shimadzu)
BA: Acetonitrile	Shim-pack XR-C8 2.2μ, 100 x 2.00 mm (Shimpack)
BB: Methanol	Shim-pack XR-Phenyl 2.2μ, 100 x 2.00 mm (Shimpack)
BC: Acetonitrile / Methanol 50/50 (v/v)	

Maximizing Efficiency for UHPLC LC-MS/MS Method Development in clinical drug monitoring

3-2. Data Recording

The first step is the evaluation of the optimal column / solvent combination using a generic gradient starting with 5% of organic solvent increasing to 95% within a specified time. This initial stage generates a viable method requiring some further optimization. The second step optimizes the

slope of the gradient as well as the solvent conditions. Several different conditions were then performed during an overnight analysis. Table 2 shows the used columns and solvents.

3-3. Data comparison

A total number of 162 different combinations were analyzed and evaluated for the best separation and peak intensities (Fig. 4).




Fig. 4. shows examples for poor, medium and good results

3-4. Final method

Flow rate: 0.4 mL / min
 Column : Synergie Hydro-RP
 Solvent A: 5 mM Ammonium acetate , pH 8
 Solvent B: Methanol
 Oven temp.: 50°C

Gradient :
 0 min: 30 % B
 5 min: 85 % B
 5.01 min: 95 % B
 8 min: 95 % B
 8.01 min: 30 % B
 10 min: Stop

Maximizing Efficiency for UHPLC LC-MS/MS Method Development in clinical drug monitoring

4. Conclusions

The Combination of the method scouting software tool coupled Shimadzu's ultrafast LCMS-8040 Triple Quad Mass analyzer is a unique tool for fast and easy method development of LC-MS/MS methods. The chromatographic separation of 14 different drugs as well as their identification and quantification was established successfully within one working day.



LCMS-8040 triple quadrupole mass spectrometer